Market news

On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year’s figure. Management also raised its full year adjusted EBITDA outlook. Yet full year revenue guidance stayed exactly […]

The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Detailed price information for Cormedix Inc (CRMD-Q) from The Globe and Mail including charting and trades.

CorMedix 2Q26 update: DefenCath-driven profits, $101.9M revenue, $256.7M cash, discounted valuation, and risks ahead. Click here to read more on CRMD stock.

Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

CorMedix's (CRMD) last major customer for its DefenCath solution could buoy 2026 volumes and back fr

Moby summary of CorMedix Inc.'s Q2 2026 earnings call

CorMedix (NASDAQ:CRMD) reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business. Recent Corporate Highlights:

CorMedix expects to submit its supplemental Rezzayo application in Q3, with a potential FDA decision in the first half of 2027.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Cormedix Inc (CRMD-Q) from The Globe and Mail including charting and trades.

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, August 13th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link About CorMedixCorMedix Therapeutics is a biopharmaceutical company focused on